查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1990539

FASN抑制劑市場：全球市場預測（依適應症、產品類型、劑型、最終用戶和通路分類），2026-2032年

FASN Inhibitor Market by Indication, Product Type, Formulation, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 FASN 抑制劑市場在 2025 年的價值為 3.8687 億美元，在 2026 年成長至 4.1809 億美元，到 2032 年達到 6.8794 億美元，複合年成長率為 8.57%。

主要市場統計數據
基準年 2025 3.8687億美元
預計年份：2026年 4.1809億美元
預測年份 2032 6.8794億美元
複合年成長率 (%) 8.57%

對脂肪酸合成酶抑制劑計畫的治療證據、轉化研究趨勢和關鍵臨床開發挑戰進行了權威概述。

脂肪酸合成酶（FASN）抑制劑透過靶向脂質代謝異常（許多固體癌的特徵性表現），已成為腫瘤治療領域一個極具前景的方向。過去十年，科學界已累積了大量臨床前證據，顯示FASN誘導的脂質生物合成與腫瘤生長、轉移和治療抗藥性密切相關。這些治療證據推動了轉化研究的蓬勃發展，旨在將代謝脆弱性轉化為臨床可應用的干涉措施。因此，FASN抑制如今已成為精準腫瘤學、代謝生物學和聯合治療策略的交會點。

科學突破、適應性調查方法和商業性需求的融合如何重塑 FASN 抑制劑的開發策略。

FASN抑制劑的研發格局正經歷著一場變革性的轉變，這主要由科學、臨床和商業性因素共同驅動。腫瘤代謝研究的進展揭示了FASN活性與致癌訊號通路之間的機制聯繫，從而改善了標靶驗證和生物標記策略。同時，臨床試驗設計也在不斷發展，引入了適應性通訊協定、篩選患者群以及早期採用動態終點，以加快決定是否繼續或終止研發的進程。這些調查方法的改進改變了研發者的風險狀況，並重塑了生技公司與大型製藥公司之間的夥伴關係動態。

2025 年美國關稅政策調整對生技藥品研發的採購、供應連續性和專案優先順序的綜合營運和策略影響。

近期對2025年貿易政策和關稅結構的調整正對生物製藥供應鏈產生累積影響，並波及到與FASN抑制劑計畫相關的研究、臨床開發和生產活動。某些化學品、實驗室耗材和專用設備的進口關稅提高，增加了活性藥物成分和關鍵原料的直接採購成本。這些成本壓力促使專案發起公司重新評估其供應商組合，協商長期契約，並在某些情況下加快對國內供應商或替代供應商的認證，以降低未來貿易中斷帶來的風險。

精細的細分洞察，將特定適應症的生物學、治療方法多樣性、製劑選擇、終端用戶趨勢和管道要求與轉換優先順序相結合。

細分市場層面的趨勢揭示了每種適應症、產品類型、劑型、終端用戶和分銷管道所面臨的獨特機會和挑戰，因此需要製定個人化的開發和商業化策略。治療領域包括乳癌、肝細胞癌、卵巢癌和攝護腺癌，每種適應症都有獨特的分子背景、患者群體和標準治療方案，這些都會影響臨床概念驗證。

決定全球主要地區監管參與程度、臨床試驗效率和商業化路徑的區域因素和跨國商業策略。

地理因素對全球主要地區的臨床開發、供應鏈設計、監管互動和商業化路徑的影響方式各不相同。在美洲，監管合作、支付方趨勢和臨床試驗基礎設施支持快速概念驗證研究和早期商業化策略，尤其注重產生能夠證明顯著臨床效益和安全性的證據。歐洲、中東和非洲（EMEA）地區的監管環境和報銷機制則較為複雜，各國決策、區域參考定價機制以及不斷變化的臨床試驗網路，都需要量身定做的監管應對措施和市場准入策略，以最大限度地提高市場滲透率和市場接受度。

透過模式專業知識、生物標記整合和夥伴關係模式，制定競爭和企業策略，使開發商脫穎而出，並推動 FASN 抑制劑產品組合的發展。

FASN抑制劑研發領域的競爭格局呈現出兩極化的特點：既有專注於早期候選藥物研發的專業生物技術公司，也有透過合作、授權和內部專案探索代謝腫瘤學的大型製藥企業。主要企業除了擁有專有的化學分型、抗體工程技術或胜肽設計平台外，還致力於透過整合生物標記開發和伴隨診斷策略來實現策略差異化。從與學術機構合作進行標靶檢驗，到與成熟的腫瘤治療公司達成共同開發契約，各種合作模式在加速臨床應用和利用後期研發經驗方面繼續發揮核心作用。

為開發商提供切實可行的策略行動，透過協調生物標記主導的臨床試驗、聯合治療、彈性供應鏈和支付方合作，加速臨床和商業性成功。

產業領導者應採取積極主動的綜合策略，將科學檢驗、臨床策略、生產韌性和商業規劃相結合，以充分釋放FASN標靶治療方法的潛力。首先，應優先進行轉化研究項目，納入預測性生物標記和動態終點，以降低臨床開發風險並最佳化患者選擇。其次，應儘早設計採用成熟治療方法的聯合治療研究，以確保在後期投資前充分了解安全性和給藥順序等因素。這些措施將增強與監管機構和支付方諮詢所需的證據，從而提高獲得具有臨床意義的療效的可能性。

結合文獻整合、監管分析、專家訪談和營運場景評估的多方面研究框架，得出基於證據的策略見解。

本分析整合了跨學科調查方法，結合專家訪談、同行評審文獻綜述、監管指南審查和營運案例研究分析，以得出可操作的見解。該方法首先系統地回顧臨床前和臨床出版物，以確定FASN抑制的科學基礎，並識別檢驗的生物標記、機制數據和安全性訊號。接下來，審查監管文件和指南，以闡明與臨床開發相關的路徑，並確定關於生物標記使用和聯合治療核准的不斷變化的預期。

將科學潛力、實際情況和戰略重點進行簡潔整合，以將 FASN 抑制從轉化成功轉化為臨床影響。

總之，FASN抑制劑透過標靶腫瘤脂質代謝，在腫瘤治療領域佔有重要的策略地位，為解決多種腫瘤類型的治療抗藥性和生物依賴性問題提供了機會。該領域正從機制檢驗轉向以生物標記為導向的臨床開發和可執行的商業化計劃，並透過治療方法多樣化和製劑創新來拓展治療手段。 2025年的關稅調整和供應鏈波動帶來了營運挑戰，但同時也促使企業進行策略供應商多元化和生產最佳化，從而增強長期專案的韌性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 FASN抑制劑市場：依適應症分類

  • 乳癌
  • 肝細胞癌
  • 卵巢癌
  • 攝護腺癌

第9章 FASN抑制劑市場：依產品類型分類

  • 抗體抑制劑
  • 胜肽抑制劑
  • 低分子化合物

第10章：以劑型分類的FASN抑制劑市場

  • 注射藥物
    • 肌肉內部
    • 靜脈
  • 口服

第11章 FASN抑制劑市場：依最終用戶分類

  • 醫院
  • 研究機構
  • 專科診所

第12章 FASN抑制劑市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 FASN抑制劑市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 FASN抑制劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 FASN抑制劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國FASN抑制劑市場

第17章：中國FASN抑制劑市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Abcam Limited
  • Antipodean Pharmaceuticals
  • Ascletis Pharma Inc.
  • Bio-Techne Corporation
  • Boehringer Ingelheim International GmbH
  • Cayman Chemical Company
  • Enzo Biochem, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Manus Aktteva Biopharma LLP
  • MedChemExpress
  • Merck KGaA
  • Niksan Pharmaceutical
  • Pfizer Inc.
  • Sagimet Biosciences
  • Santa Cruz Biotechnology, Inc.
  • Spansules Pharma
  • Takeda Pharmaceutical Company Limited
  • VWR International by Avantor
Product Code: MRR-6A132FD32B24

The FASN Inhibitor Market was valued at USD 386.87 million in 2025 and is projected to grow to USD 418.09 million in 2026, with a CAGR of 8.57%, reaching USD 687.94 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 386.87 million
Estimated Year [2026] USD 418.09 million
Forecast Year [2032] USD 687.94 million
CAGR (%) 8.57%

An authoritative orientation to the therapeutic rationale, translational momentum, and clinical development imperatives shaping fatty acid synthase inhibitor programs

Fatty acid synthase (FASN) inhibitors represent a promising therapeutic axis within oncology by targeting aberrant lipid metabolism, a hallmark of several solid tumors. Over the past decade, the scientific community has consolidated preclinical evidence that links FASN-driven lipogenesis to tumor growth, metastasis, and treatment resistance. This therapeutic rationale has catalyzed a wave of translational efforts aimed at converting metabolic vulnerabilities into clinically actionable interventions. As a result, FASN inhibition is now positioned at the intersection of precision oncology, metabolic biology, and combination therapy strategies.

Clinicians and researchers have increasingly focused on identifying predictive biomarkers and optimizing drug delivery modalities to enhance the therapeutic index of FASN-targeted agents. Concurrent advances in medicinal chemistry and biologics engineering have broadened the spectrum of product types under investigation, spanning small molecules, peptides, and antibody-based approaches. As the field advances, important considerations include patient selection algorithms, combinatorial regimens with standard-of-care therapies, and vigilant assessment of safety profiles related to systemic lipid modulation. Together, these elements shape a dynamic early-to-mid stage development environment that warrants strategic attention from developers, research institutions, and clinical stakeholders.

How converging scientific breakthroughs, adaptive clinical methodologies, and commercial imperatives are reshaping development strategies for FASN inhibitors

The landscape for FASN inhibitor development is undergoing transformative shifts driven by converging scientific, clinical, and commercial forces. Advances in tumor metabolism research have clarified mechanistic links between FASN activity and oncogenic signaling, which in turn has refined target validation and biomarker strategies. At the same time, clinical trial design has evolved to incorporate adaptive protocols, enriched patient cohorts, and earlier integration of pharmacodynamic endpoints to accelerate go/no-go decisions. These methodological refinements have altered risk profiles for developers and reshaped partnership dynamics between biotechs and larger pharmaceutical sponsors.

On the technological front, improvements in formulation science and delivery systems have enabled more precise targeting and dosing flexibility, opening opportunities for both systemic and localized administration. Regulatory agencies have signaled openness to robust biomarker-driven pathways and combination study designs, prompting sponsors to align translational research with regulatory expectations earlier in development. Commercially, payers and health systems are increasingly attentive to value demonstrations that connect metabolic modulation to durable clinical benefit and real-world outcomes. Together, these shifts are redefining program priorities and elevating the importance of integrated strategies that span discovery, clinical development, manufacturing, and market access planning.

The aggregate operational and strategic consequences of adjusted United States tariff policies in 2025 on procurement, supply continuity, and program prioritization within biologics development

Recent adjustments to trade policies and tariff structures in 2025 have exerted cumulative effects on the biopharmaceutical supply chain that ripple through research, clinical development, and manufacturing activities relevant to FASN inhibitor programs. Heightened import duties on selected chemicals, laboratory consumables, and specialized equipment have increased direct procurement costs for active pharmaceutical ingredients and critical raw materials. These cost pressures have prompted sponsors to reassess supplier portfolios, negotiate longer-term contracts, and, in some cases, accelerate qualification of domestic or alternative suppliers to mitigate exposure to future trade disruptions.

Beyond direct input costs, tariff-driven supply chain friction has influenced logistics and lead times for clinical supplies and investigational medicinal products, requiring sponsors to build greater inventory buffers and contingency plans. This operational response has implications for trial timelines and budget allocations, especially for programs that rely on specialized reagents and outsourced manufacturing. Moreover, the cumulative tariff environment has encouraged more strategic sourcing decisions, including regional diversification of manufacturing and an increased emphasis on upstream vertical integration where feasible. While such adjustments can safeguard continuity, they also demand capital and managerial bandwidth, thereby influencing program prioritization and partnership structures across the FASN inhibitor ecosystem.

Nuanced segmentation insights that align indication-specific biology, modality diversity, formulation choices, end-user dynamics, and channel imperatives for translational prioritization

Segment-level dynamics reveal differentiated opportunities and constraints across indications, product types, formulations, end users, and distribution channels, each requiring tailored development and commercialization strategies. The therapeutic focus spans breast cancer, hepatocellular carcinoma, ovarian cancer, and prostate cancer, with each indication presenting distinct molecular contexts, patient populations, and standard-of-care backdrops that influence trial design and positioning. Product development pathways include antibody inhibitors, peptide inhibitors, and small molecule approaches, each with unique discovery challenges, development timelines, and regulatory considerations that affect the pathway to clinical proof-of-concept.

Formulation and route of administration considerations further shape clinical development and market access approaches: both injectable and oral formulations are under evaluation, with injectable options subdivided into intramuscular and intravenous modalities that demand specific formulation expertise and administration logistics. End users include hospitals, research institutes, and specialty clinics that differ in procurement practices, clinical trial participation, and adoption patterns. Distribution channels comprise hospital pharmacies, online pharmacies, and retail pharmacies, each presenting distinct compliance, dispensing, and reimbursement landscapes. Integrating insights across these segmentation dimensions enables sponsors to prioritize assets, tailor clinical development plans, and design commercial strategies that align with clinician workflows and patient preferences.

Regional considerations and cross-border operational strategies that determine regulatory engagement, trial execution efficiency, and commercialization pathways across major global territories

Geographic dynamics influence clinical development, supply chain design, regulatory engagement, and commercialization pathways in distinct ways across primary global regions. In the Americas, regulatory interactions, payer dynamics, and clinical trial infrastructure support rapid proof-of-concept studies and early commercialization strategies, with particular emphasis on evidence generation that demonstrates meaningful clinical benefit and safety. Europe, Middle East & Africa presents a heterogeneous regulatory and reimbursement landscape where country-level decision-making, regional reference pricing mechanisms, and variable clinical trial networks necessitate tailored regulatory and market access approaches to maximize penetration and uptake.

Asia-Pacific encompasses diverse healthcare systems, growing clinical research capacity, and manufacturing hubs that can offer both rapid patient enrollment and cost-efficient production capabilities. Sponsors frequently leverage this region for late-stage trial recruitment and supply chain flexibility, while also navigating complex regulatory timelines and local clinical practice patterns. Across all regions, successful programs harmonize regulatory science, local stakeholder engagement, and operational logistics to optimize trial execution and commercialization readiness, while also recognizing regional differences in standard-of-care, diagnostic infrastructure, and payer expectations.

Competitive dynamics and corporate strategies that differentiate developers through modality expertise, biomarker integration, and partnership models to advance FASN inhibitor portfolios

The competitive landscape for FASN inhibitor development is characterized by a mix of specialized biotechs advancing early-stage candidates and larger pharmaceutical companies exploring metabolic oncology through partnerships, in-licensing, and internal programs. Key companies emphasize strategic differentiation through proprietary chemotypes, antibody engineering expertise, or peptide design platforms, as well as through integrated biomarker development and companion diagnostic strategies. Collaboration models-ranging from academic partnerships for target validation to co-development agreements with established oncology sponsors-remain central to accelerating clinical translation and accessing late-stage development expertise.

Strategic priorities among leading organizations include optimizing target engagement, minimizing off-target metabolic consequences, and designing combination regimens that complement established therapeutic modalities such as endocrine therapy, targeted agents, and immuno-oncology treatments. Additionally, companies are investing in manufacturing capabilities and formulation science to support scalable production and to offer distinct dosing modalities that meet clinical and marketplace needs. Intellectual property strategies, data exclusivity planning, and early payer engagement are also prominent considerations as firms seek to protect value and create pathways to sustainable adoption in clinical practice.

Practical strategic actions for developers that align biomarker-driven trials, combination regimens, resilient supply chains, and payer engagement to accelerate clinical and commercial success

Industry leaders should adopt a proactive, integrated approach that aligns scientific validation, clinical strategy, manufacturing resilience, and commercial planning to unlock the broader potential of FASN-directed therapies. First, prioritize translational programs that incorporate predictive biomarkers and pharmacodynamic endpoints to de-risk clinical development and improve patient selection. Second, design combination studies with established therapeutic regimens early, ensuring that safety and sequencing considerations are understood before late-stage investment. These steps will enhance the evidence package required for regulatory and payer discussions and increase the probability of clinically meaningful outcomes.

Operationally, diversify supplier networks and qualify alternative manufacturing partners to mitigate potential supply chain and tariff-related disruptions. Invest in formulation strategies that enable both oral and injectable dosing where scientifically justified to maximize clinical applicability and patient convenience. From a commercial perspective, engage payers and key clinical opinion leaders early to define value frameworks and real-world evidence needs. Finally, pursue flexible collaboration models that allow smaller innovators to leverage the development horsepower of larger organizations while preserving upside through smart deal structures and milestone-based partnerships.

A multi-method research framework combining literature synthesis, regulatory analysis, expert consultation, and operational scenario assessment to produce evidence-based strategic insights

This analysis integrates a cross-disciplinary research methodology that combines expert interviews, peer-reviewed literature synthesis, regulatory guidance review, and operational case study analysis to produce actionable insights. The approach begins with a systematic review of preclinical and clinical publications to establish the scientific underpinning of FASN inhibition and to identify validated biomarkers, mechanistic data, and safety signals. Next, regulatory documents and guidance were examined to map relevant pathways for clinical development and to identify evolving expectations around biomarker use and combination therapy approvals.

Complementing the literature-based approach, the methodology includes structured consultations with clinical investigators, formulation scientists, regulatory strategists, and manufacturing specialists to ground findings in operational realities. Supply chain assessments evaluated sourcing risk, potential tariff implications, and mitigation strategies through scenario-based analysis. Finally, competitive and commercial insights were derived from product development disclosures, partnership announcements, and public corporate filings to identify strategic trajectories and common success factors. This triangulated methodology ensures the findings are both evidence-based and practical for decision-makers.

A concise synthesis of scientific promise, operational realities, and strategic priorities required to translate FASN inhibition from translational success to clinical impact

In sum, FASN inhibitors occupy a strategically important niche in oncology by targeting tumor lipid metabolism, offering opportunities to address treatment resistance and biological dependencies across multiple tumor types. The field is transitioning from mechanistic validation toward biomarker-enabled clinical development and pragmatic commercial planning, with modality diversity and formulation innovation expanding the therapeutic toolkit. While tariff adjustments and supply chain dynamics in 2025 have introduced operational challenges, they have also sparked strategic supplier diversification and manufacturing optimization that can strengthen long-term program resilience.

Moving forward, successful programs will integrate translational rigor, adaptive clinical design, and supply chain foresight, while engaging regulatory and payer stakeholders early to clarify evidence requirements. Collaboration across academia, industry, and clinical networks will remain essential to validate combinations and identify patient cohorts most likely to benefit. With disciplined execution and a focus on value demonstration, developers can translate preclinical promise into therapies that deliver meaningful outcomes for patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. FASN Inhibitor Market, by Indication

  • 8.1. Breast Cancer
  • 8.2. Hepatocellular Carcinoma
  • 8.3. Ovarian Cancer
  • 8.4. Prostate Cancer

9. FASN Inhibitor Market, by Product Type

  • 9.1. Antibody Inhibitor
  • 9.2. Peptide Inhibitor
  • 9.3. Small Molecule

10. FASN Inhibitor Market, by Formulation

  • 10.1. Injectable
    • 10.1.1. Intramuscular
    • 10.1.2. Intravenous
  • 10.2. Oral

11. FASN Inhibitor Market, by End User

  • 11.1. Hospitals
  • 11.2. Research Institutes
  • 11.3. Specialty Clinics

12. FASN Inhibitor Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. FASN Inhibitor Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. FASN Inhibitor Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. FASN Inhibitor Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States FASN Inhibitor Market

17. China FASN Inhibitor Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Abcam Limited
  • 18.7. Antipodean Pharmaceuticals
  • 18.8. Ascletis Pharma Inc.
  • 18.9. Bio-Techne Corporation
  • 18.10. Boehringer Ingelheim International GmbH
  • 18.11. Cayman Chemical Company
  • 18.12. Enzo Biochem, Inc.
  • 18.13. Gilead Sciences, Inc.
  • 18.14. GlaxoSmithKline PLC
  • 18.15. Johnson & Johnson Services, Inc.
  • 18.16. Manus Aktteva Biopharma LLP
  • 18.17. MedChemExpress
  • 18.18. Merck KGaA
  • 18.19. Niksan Pharmaceutical
  • 18.20. Pfizer Inc.
  • 18.21. Sagimet Biosciences
  • 18.22. Santa Cruz Biotechnology, Inc.
  • 18.23. Spansules Pharma
  • 18.24. Takeda Pharmaceutical Company Limited
  • 18.25. VWR International by Avantor

LIST OF FIGURES

  • FIGURE 1. GLOBAL FASN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FASN INHIBITOR MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FASN INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FASN INHIBITOR MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FASN INHIBITOR MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FASN INHIBITOR MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FASN INHIBITOR MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES FASN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA FASN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FASN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FASN INHIBITOR MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FASN INHIBITOR MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FASN INHIBITOR MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FASN INHIBITOR MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FASN INHIBITOR MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FASN INHIBITOR MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FASN INHIBITOR MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FASN INHIBITOR MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FASN INHIBITOR MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FASN INHIBITOR MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FASN INHIBITOR MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FASN INHIBITOR MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FASN INHIBITOR MARKET SIZE, BY ANTIBODY INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FASN INHIBITOR MARKET SIZE, BY ANTIBODY INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FASN INHIBITOR MARKET SIZE, BY ANTIBODY INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FASN INHIBITOR MARKET SIZE, BY PEPTIDE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FASN INHIBITOR MARKET SIZE, BY PEPTIDE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FASN INHIBITOR MARKET SIZE, BY PEPTIDE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FASN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FASN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FASN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FASN INHIBITOR MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FASN INHIBITOR MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FASN INHIBITOR MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FASN INHIBITOR MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FASN INHIBITOR MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FASN INHIBITOR MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FASN INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FASN INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FASN INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FASN INHIBITOR MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FASN INHIBITOR MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FASN INHIBITOR MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FASN INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FASN INHIBITOR MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FASN INHIBITOR MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FASN INHIBITOR MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FASN INHIBITOR MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FASN INHIBITOR MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FASN INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FASN INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FASN INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FASN INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FASN INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FASN INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FASN INHIBITOR MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FASN INHIBITOR MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FASN INHIBITOR MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FASN INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FASN INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FASN INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FASN INHIBITOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS FASN INHIBITOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL FASN INHIBITOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. GCC FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GCC FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. GCC FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. GCC FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 128. GCC FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. GCC FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. G7 FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. G7 FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. G7 FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. G7 FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 149. G7 FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. G7 FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. NATO FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. NATO FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. NATO FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NATO FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 156. NATO FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. NATO FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES FASN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA FASN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)